alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 201–225 of 653 studies of type cross-sectional study · free to read (page 9 of 27) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Lancet. Neurology 2012-11-06

These findings contribute to the understanding of preclinical familial Alzheimer's disease and help set the stage for assessment of amyloid-modifying treatments in the prevention of familial Alzheimer's disease. 1 key finding →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Unmet needs of community-residing persons with dementia and their informal caregivers: findings from the maximizing independence at home study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of the American Geriatrics Society 2013-12-01

Many community-residing PWD and their caregivers have unmet dementia-related needs for care, services, and support. 4 key findings →

Design: cross-sectional Participants: 254 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of neurology 2008-08-01

Older age and vascular disease, particularly among African Americans, are associated with increased brain atrophy and WMH burden. 4 key findings →

Design: cross-sectional Participants: 769 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations of the Mediterranean diet with cognitive and neuroimaging phenotypes of dementia in healthy older adults

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The American journal of clinical nutrition 2019-02-01

When compared with the Low MedDiet group, the High MedDiet group was associated with better L&M performance and larger dentate gyri. 5 key findings →

Design: cross-sectional Participants: 82 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. EMBO molecular medicine 2023-01-09

Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. 4 key findings →

Design: cross-sectional Participants: 70 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer Disease Biomarkers and Subjective Cognitive Decline Among Hispanic and/or Latino Adults

✓ Peer-reviewed alzhub usefulness score 57 out of 100. JAMA network open 2025-09-02

Subjective cognitive decline (SCD) may be an early indicator of Alzheimer disease and related dementias (ADRD), yet its association with plasma biomarkers remains unclear among middle-aged and older adults (aged 50-86 years). 4 key findings →

Design: cross-sectional Participants: 5,712 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Frontiers in neurology 2021-09-07

Plasma-based biomarkers would be potential biomarkers for early diagnosis of Alzheimer's disease (AD) because they are more available and cost-effective than cerebrospinal fluid (CSF) or neuroimaging. 4 key findings →

Design: cross-sectional Participants: 185 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Differences in Home Health Services and Outcomes Between Traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 57 out of 100. JAMA Health Forum 2024-03-01

Of 285 297 total patients, 180 283 (63.2%) were female; 586 (0.2%) were American Indian/Alaska Native, 8957 (3.1%) Asian, 28 694 (10.1%) Black, 7406 (2.6%) Hispanic, 1959 (0.7%) Native Hawaiian/Pacific Islander, 237 017 (83.1%) non-Hispanic White, and 678 (0.2%) multiracial individuals. 5 key findings →

Design: cross-sectional Participants: 178 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of dementia in Singapore: Changes across a decade

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer s & Dementia 2025-01-27

The weighted prevalence of dementia based on the 10/66 Diagnostic Research Group (DRG) criteria was 8.8% (95% confidence interval [CI]: 7.3-10.7) in the WiSE 2023 study compared to 10% in the WiSE 2013 study (95% CI: 8.7-11.5). 5 key findings →

Design: cross-sectional Participants: 2,010 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Income, Race-Ethnicity, and Dementia Risk Factors in the United States

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2025-11-12

There were 13,145 individuals with risk factor data between 2015 and 2018 (51.1% aged 18-44, 31.0% aged 45-64, and 17.9% aged ≥65 years; 51.5% female after survey-weighting). 5 key findings →

Design: cross-sectional Participants: 13,145 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Proteins Involved in Endothelial Function and Inflammation Are Implicated in Cerebral Small Vessel Disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Stroke 2025-01-17

). Moreover, 12 proteins related to endothelial function and inflammation were associated with neuroimaging features of SVD. 4 key findings →

Design: cross-sectional Participants: 35 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Age-stratified associations between severe mental illness, dementia, and ischemic stroke: findings from the PADRIS-PRESTO cohort

✓ Peer-reviewed alzhub usefulness score 57 out of 100. European Neuropsychopharmacology 2026-04-20

People with severe mental illnesses (SMIs), including schizophrenia spectrum disorders (SSD), major depressive disorder (MDD), and bipolar disorder (BD), experience elevated rates of physical comorbidity and premature mortality. 3 key findings →

Design: cross-sectional Participants: 694,086 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

[18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of neuroinflammation 2023-03-11

We selected the cerebellum as a pseudo-reference region based on the immunohistochemical comparison of age-matched PS2APP and WT mice. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2024-09-27

Our results reveal a spatial association between the epileptogenic focus and tau deposition, amyloid deposition, and neurodegeneration in early clinical stages of AD. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2006-10-01

Frontotemporal dementia and Alzheimer disease display different spatial distributions of hypoperfusion on arterial spin labeling MRI. 2 key findings →

Design: cross-sectional Participants: 21 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017-11-30

PERSI showed superior test-retest reproducibility (1.84%) and group separation ability (cross-sectional Cohen d = 9.45; longitudinal Cohen d = 2.34) compared with other reference regions. 4 key findings →

Design: cross-sectional Participants: 215 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effect of Area-Level Socioeconomic Deprivation on Risk of Cognitive Dysfunction in Older Adults

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of the American Geriatrics Society 2018-02-12

This analysis combining data from two health systems shows that area deprivation is an independent risk factor for cognitive dysfunction in older adults. 3 key findings →

Design: cross-sectional Participants: 5,186 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events